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Abstract: Islets of Langerhans are islands of endocrine cells scattered throughout the pancreas.
A number of new studies have pointed to the potential for conversion of non-β islet cells in to
insulin-producing β-cells to replenish β-cell mass as a means to treat diabetes. Understanding normal
islet cell mass and function is important to help advance such treatment modalities: what should
be the target islet/β-cell mass, does islet architecture matter to energy homeostasis, and what may
happen if we lose a particular population of islet cells in favour of β-cells? These are all questions
to which we will need answers for islet replacement therapy by transdifferentiation of non-β islet
cells to be a reality in humans. We know a fair amount about the biology of β-cells but not quite
as much about the other islet cell types. Until recently, we have not had a good grasp of islet mass
and distribution in the human pancreas. In this review, we will look at current data on islet cells,
focussing more on non-β cells, and on human pancreatic islet mass and distribution.
Keywords: islets of Langerhans; insulin; glucagon; somatostatin; pancreatic polypeptide; ghrelin;
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1. Introduction
The islands or (more commonly) islets of Langerhans, first described by their namesake- Paul
Langerhans- in 1969, are islands of mixed populations of endocrine cells that are scattered in the
parenchyma of the pancreas. Islets of Langerhans have been much studied in the context of diabetes
due to the hormones produced and secreted from the cells which form these micro-organs, which are
involved in the regulation of glucose homeostasis. The discovery of insulin, and the demonstration that
it can lower blood glucose in dogs, by Frederick Banting and Charles Best in 1921, and its subsequent
development for clinical use, in collaboration with John Macleod and James Collip, led to the award of
the Nobel Prize in Physiology or Medicine to Banting and Macleod in 1923. Since then, the biology of
the insulin producing β-cells in the islet came under much scrutiny as the loss of β-cell function, hence
the loss of insulin, was associated with diabetes. Initially, much more associated with type 1 diabetes,
which is characterised by the loss of β-cell mass due to autoimmune attack of this cell type, loss of
functional β-cell mass is now also associated with type 2 diabetes (T2D).
There are multiple developmental cues for islet formation ranging from external cues such as
nutritional status (i.e., the maternal nutritional state) to signals from the developing foetus e.g., from
the central nervous system [1]. Replenishment of β-cell mass following the loss of significant β-cell
mass (circa 90%) in mice has been shown to lead to activation of β-cell duplication [2,3]. Recuperation
of β-cell mass following >90% loss of β-cell mass was shown to be via transdifferentiation of other
islet cells, e.g., α-cells [4] and δ-cells [5], into β-cells. Data from the literature indicate that whilst
loss of pancreatic β-cell mass may lead to disease, there is little or no effect on physiology from near
complete loss of α-cell mass, responsible for secretion of glucagon (the counter hormone to insulin) in
rodents [6]. With the advent of the possibility to switch islet cell identity as a means to alter islet cell
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mass as treatment for diabetes [4,5,7,8], it is perhaps timely to review current information on islet cell
mass and the function of the different islet cell types.
2. Islet Distribution in the Pancreas: Structure, Size, Location
The total number of islets in a human pancreas has been estimated to be between 3.2 and
14.8 million, with a total islet volume of 0.5 to 2.0 cm3 [9–14]. The cellular composition and architecture
of pancreatic islets differ between and within species [15,16]. The inter-species differences have
previously been shown to correlate with functional differences [17]. Human islets consist of circa 30%
glucagon-producing α-cells, circa 60% insulin producing β-cells, with the remainder circa 10% made
up of δ-cells (somatostatin-producing), γ- or PP cells (pancreatic polypeptide-producing), and ε-cells
(ghrelin-producing) [9,17–20], with these endocrine cells randomly distributed throughout the islet [15–17].
Rodent islets are widely used in biomedical research, and have a different architecture with a core of
β-cells surrounded by the other endocrine cell types [16,21–23].
Recently, Ionescu–Tirgoviste and colleagues [9] performed a careful evaluation of islet
characteristics from a healthy human pancreas by analysing pancreatic sections to produce a
three-dimensional islet distribution map. The study revealed that the human pancreas contains
on average 3.2 million islets, with a mean islet diameter of 108.92 µm (±6.27 µm), and a mean islet
volume of 0.00069 µL (±0.00011 µL) [9]. The majority of islets (~66%) have a surface area of between
1000 and 10,000 µm2. Approximately 24% and 9% of islets had a surface area of more than 100,000 µm2
and less than 1000 µm2, respectively. The islets appear to have a threshold surface area of about
100,000 µm2, where “islets” that have apparently larger surface area than the threshold were made up
of clusters of islets [9]. The smaller islets tended to cluster around blood vessels [9]. When islet surface
area and distribution were averaged over pancreas section area, Ionescu-Tirgoviste and colleagues
concluded that there was a uniform scattering of islets in the body of the pancreas, with the islets
adopting an overall spherical structure [9]. This is in contrast to previous reports indicating an uneven
distribution of islets in human [24] and rodent pancreas [21,25–32], although the differences may be
due to differences in the methodologies used for estimating β-cell mass.
Islet mass and distribution in the pancreas may be an important consideration in light of the
known metabolic consequences of pancreatectomy, where patients suffer a sudden loss of islet cell mass
from surgical resection of the pancreas. Patients that have undergone a 50% (partial) pancreatectomy
have reduced insulin secretion (circa 50%) but the region of pancreas that is removed was reported
to have different metabolic impact [33]. Thus, removal of the pancreatic tail led to post-operative
elevated fasting glucose and post-challenge glycaemia, whilst removal of the pancreatic head caused
an improvement in oral glucose tolerance [33]. Earlier studies involving the loss of the pancreatic tail
in human subjects also reported lowered insulin secretion and glucose tolerance in patients one year
after partial pancreatectomy [34]. Intriguingly, the data from the pancreatectomy studies, together with
Ionescu-Tirgoviste and colleagues’ report [9] that there was a uniform scattering of islets in the body of
the pancreas, may imply that there are functional differences between the islets in the head and the
tail of the pancreas. Thus, it would appear, not all islets are the same and there may be differences in
the islet population in the head vs the tail of the pancreas. Such considerations are important beyond
academic curiosity. The head and the tail of the pancreas have different developmental origins: the
head of the pancreas is formed from the dorsal and ventral pancreatic bud, and the body and tail of the
pancreas are formed from the ventral pancreatic bud [35]. Studies in rodents have previously shown
that islets originating from the dorsal pancreatic bud had greater capacity to secrete and synthesise
insulin than islets of ventral bud origins [26–29], perhaps hinting at potential programming differences
during development in islets (reviewed extensively in [36]) in relation to their function and adaptive
responses in adult life. This in turn may have an impact on the therapeutic strategies that may be
pliable to increase functional β-cell mass in vivo (see Section 4 below) [26–29,33,35–38].
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3. α-Cell
It would be fair to say that a lot less is known about the glucagon producing α-cell than the
insulin producing β-cell. Glucagon is the counter hormone to insulin, and is typical of the fasted
state. The concerted regulation of glucagon and insulin secretion is a major mechanism for the
regulation of blood glucose. The major function of the counter-regulatory response is the prevention
of hypoglycaemia, a response that is impaired in diabetes [37,38]. The importance of glucagon to the
pathophysiology of T2D was first highlighted by Unger and colleagues in the bihormonal hypothesis
which states that both hypoinsulinaemia and hyperglucagonaemia contributes to hyperglycaemia in
T2D [39,40]. Thus, in T2D, α-cells display elevated glucagon secretion, enhanced glucagon secretion in
response to amino acids, and ineffective suppression of glucagon secretion by high plasma glucose [41].
The importance of the regulation of α-cell function in the pathophysiology of T2D is currently the
subject of intense research [42–44].
Glucagon secretion is regulated by both α-cell intrinsic and paracrine mechanisms. For example,
it has been proposed that hyperglucagonaemia in T2D may be a result of the loss of intrinsic
regulatory mechanism by glucose and amino acids, and extrinsic regulation by insulin and zinc,
in the α-cells [41,45–53]. However, the loss of sensitivity to nutrients, insulin and zinc as mechanisms
for hyperglucagonaemia have all been disputed [54–58]. The gut hormones—Glucagon-Like Peptide
1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP)—have been proposed to be important in the
regulation of glucagon secretion [59–66]. Additionally, there is evidence to suggest that GLP-1 can
be produced in human islets, possibly in α-cells [67]. Somatostatin, secreted by pancreatic δ-cells,
suppresses glucagon secretion [68–70]; it has been proposed that the inhibitory effect of GLP-1 on
glucagon secretion [71] is effected indirectly via the stimulation of somatostatin secretion by GLP-1 [72].
The islets of Langerhans are innervated and subject to the regulation by the sympathetic and
parasympathetic system such that glucagon secretion is stimulated in hypoglycaemia [73–76]. One
characteristic of T2D is the progressive loss of the stimulation of glucagon and counter-regulatory
hormones in patients treated with insulin [77,78]. Moreover, it has been reported that sympathetic
innervation during pancreatic development is required for establishment of islet architecture and
function [1], with the localisation of non-β cells a primary determinant of islet architecture [16,22,75,79].
Thus, the loss of non-β cell e.g. for the transdifferentiation into β-cells, may lead to the loss overall
islet architecture, with implications on islet function.
In summary, the current evidence indicates that the intrinsic, nervous and paracrine regulation of
glucagon secretion are not mutually exclusive, and likely act in concert [43,80].
Recently, Collombat and colleagues have demonstrated the potential to transdifferentiate
endogenous α-cells in to β-like cells to replenish β-cell function through the administration of
gamma aminobutyric acid (GABA) [7,8]. Furthermore, the authors showed that there was a
continuous replenishment of glucagon-positive cells indicating that GABA treatment, not only induces
transdifferentiation of α-cells in to β-like cells, but also maintains an α-cell pool [8]. This is important
as it suggests that this treatment may be able to maintain the overall proportion of islet cell types
(see Figure 1), although it is currently clear whether this will have effects on islet architecture and
function in the long term. Nevertheless, this is a particularly intriguing finding as, whilst it has
previously been demonstrated that near complete ablation of α-cells in rodents had little physiological
effect [6], partial pancreatectomy in humans have been shown to lead to enhanced responsiveness to
glucagon [81], and to secretion of glucagon from extra-pancreatic sites [82,83], both of which leads
to altered glucose handling. Thus, although it is useful to be able to make β-like cells from α-cells,
maintaining an α-cell population may also be important for the maintenance of glucose homeostasis
in humans.
In any cell (re)programming protocol, it is important to have a grasp of the identities/characteristics
of the starting cell and the destination cell. The current state of the art is likely to act as a further catalyst
for studies in to the α-cell as a result. For example, recent studies focussed on identifying β-cells based
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on expression profiles of protein-encoding genes and non-coding RNAs, are now also paralleled in
α-cells [84–105].
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4. β- ll
The β-cell is the most studied f the is et cell types and has been written about copiously [106–111],
so it would be superfluous to elabo te too much here. There are importan differences between mouse
and human β-cells which ne d to be considered in the design of therapeutic in erventions for increasing
functional β-cell mass [106].
What is a β-cell? Si plistically, it is a c ll that makes insulin that is ab e to secrete nsulin in
response to a glucose challenge. Insulin is packaged into secretory granules at concentrati ns of
circa 100 mM [112,113] a a compl x with zinc, and releas d in response t high glucose (and other
nutri t) concentrations [113] and stimulation by neurotransmitters that are released in response
to food [114]. Insulin secretion is also enha ced by the presence of incretin hormones [114].
Somatos atin, which is secreted by neighbouring δ-cells, inhibit insulin secretion [115], as do
epinephrine [116,117], galanin [118], ghrelin [119], leptin [120] and zinc ions [121]. Glucose metabolism
in the β-cell diff rs from other cell ypes n that the presence of low affinity, high transport capacity
glucose transp rter(s) (GLUT1 and 2 in humans, Glut2 in mice) [122–125], and the low affini y
hexokin se-glucokinas (GCK) [126,127] results n β-cell glucose metabolism being controlled by
substrat availability. Glycolysis and mitchondrial oxidation are clos ly coupled, due to th ack of
express on of “disallowed genes” such as lactat dehydrogenase (LDH) and th mon carboxylate
transporter (MCT1)[128]. This coupling is disrupted in islets of Langerhans from type 2 diab tic
d nors [127,129,130], with concomitant expression of disa owed g nes such as LDH and MCT1
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(reviewed in [109]). Unsurprisingly there is currently much attention on the identity of the islet cell
types, with the focus predominantly on the β-cell, especially in the context of coding and non-coding
RNA (as mentioned in the Section 3), which may be involved in the regulation of the expression these
disallowed or β-cell specific genes.
ATP production leads to closure of the ATP sensitive K+ channel (KATP) channel on the cell surface;
the subsequent membrane depolarization leads to opening of voltage-gated L-type calcium channels,
influx of calcium and the release of insulin (detailed mechanisms reviewed in [106]).
Interestingly, studies looking at β-cell regeneration in humans following partial pancreatectomy
demonstrated an increase in β-cell function [131] but not β-cell mass [132]. Additionally, the
same cohort of patients that had previously exhibited post-operative elevated fasting glucose
and post-challenge glycaemia [33], showed amelioration of both parameters circa 3 years
after pancreatectomy due to increased β-cell function [131]. Taken together with data from
Ionescu-Tirgoviste and colleagues [9], which demonstrate that islet distribution is even throughout the
human pancreas, the ability to increase function may not be dependent on the location of the β-cell in
the pancreas. This compensatory increase in β-cell function is also seen in hyper-functional islets from
obese individuals [113,133–138] which exhibit a two- to three-fold increase in insulin secretory capcity
vs. lean individuals [139,140]. The obesity model also offers a contrary view to human β-cell mass
plasticity vs pancreatectomy model: there is convincing data from various sources indicating that β-cell
regeneration may occur in pancreases from obese subjects [135,140–146]. Add to this the potential
to transdifferentiate α-cells to β-cells [8], and the potential of transplantation of human pluripotent
stem cell-derived β-like cells [147], the future seems bright for restoring β-cell mass. However, one
recent development may throw a spanner in the works. There is significant heterogeneity in β-cells
within an islet which suggests that the structure of the islet—the connections between cells and the
spatial arrangement of islet cells—may be important for the regulation of islet function [110,148,149].
Specialised insulin-positive islet hub cells—which are able to impact on the function of other cells in
the islet—may be characteristically different to other insulin-positive cells in the same islet, begging
the question as to how this difference was effected [110,148,149]. Did these cells arise from a special
subset of progenitor cells, or were they the product of a subset of developmental cues that may
have resulted from their position in the overall islet structure/pancreas? If that is the case then
simply being able to (randomly) make more β-cells may not be enough to reinstate normal glucose
homeostasis. For example, a question may be whether it is possible to replace hub β-cells through
the transdifferentiation of α-cells (see Figure 1). It is worth mentioning that diabetes is increasingly
acknowledged as a bihormonal disease and thus the study of at least both α- and β-cells are merited.
It is possible that our view of the disease will expand as we find out more about the other islet cell
types, e.g., the δ-cell (see below).
5. δ-Cell
Somatostatin secreting cells, or δ-cells, are present in the pancreatic islets, the hypothalamus,
the central nervous system, peripheral neurons and the gastrointestinal tract [68,79,150–152]. δ-cells
make up about 10% of the islet cell population. Somatostatin is a negative regulator of insulin,
glucagon and pancreatic polypeptide secretion under conditions of nutrient stimulus [116,153–156],
and in a Ca2+ dependent manner [156–161] (see Figure 1). δ-cells are electrically excitable, like α- and
β-cells (reviewed in [111]). Ghrelin [162] and urocrotin [163] act on δ-cells leading to somatostatin
release.Somatostatin is synthesised as a precursor molecule that is processed enzymatically by
protein convertase, with the 14 amino acid peptide fragment, somatostatin (SST)-14, as the major
peptide released by δ-cells [164,165]. SST-14 binds to the somatostatin receptor (of which there are
five subtypes [166], which are G-protein coupled receptors, and lead to the inhibition of adenylyl
cyclase [167] or activation of inwardly rectifying K+ channels [168].
δ-cells have been reported to transdifferentiate into β-cells in acute depletion of β-cell mass [5].
The transcription factor Pax4 is involved in the development of both β- and δ-cells during pancreatic
J. Clin. Med. 2018, 7, 54 6 of 17
specification [169]. Recently it was shown that mis-expression Pax4 in α-cells leads to conversion
to β-like cells with no evidence for δ-cell like conversion [7]. It has been shown that the δ-cell fate
is maintained by the Hhex gene [170]; loss of Hhex led to disrupted paracrine regulation of insulin
secretion, which may potentially contribute to T2D [170,171]. Similarly, as δ-cells also regulate α-cells,
loss of δ-cell mass due to transdifferentiation in to β-cells may lead to dysregulated glucagon secretion.
In short, the current evidence does not support trasndifferentiation of δ-cells to β-cells as a viable
means to replenish β-cell mass.
6. PP Cell
Pancreatic polypeptide containing cells, also called PP cells or F-cells [172–176], make up 1–2% of
the islet cell population [177–179]. PP cells are more concentrated in the head of the pancreas [180,181],
where the cells are found to occupy the outer mantle of rodent islets or lining the capillaries in
human islets [79]. Post-prandial pancreatic polypetide release is regulated by vagal and enteric
nervous input [182–185], and is responsive to arginine but not glucose sitmulation [186]. Pancreatic
polypeptide has been shown to be an inhibitor of glucagon release at low glucose [187] (see Figure 1).
The major function of PP appears to be that of a satiety hormone (reviewed in [188]).
7. Ghrelin-Positive and Other Islet Cell Types
A further three types of islet cells have been described in the literature. These cells contain
ghrelin [189,190], serotonin (enterochromaffin cells) [191,192], gastrin (G-cells) [174,193], and small
granules of unknown content (P/D1- cells) [174,191,194–197].
Of these the ghrelin positive cells have recently attracted the most interest. Ghrelin-positive cells
are mainly found in the gut [195,198–201]. Ghrelin-positive cells are also found in the islet, accounting
for circa 10% and 1% of islet cell content in foetal and adult islets, respectively [119,189,190,195]. It has
been suggested that ghrelin positive cells in the islets are in fact the P/D1 cells, which were described
as containing an unknown hormone, as the two cell types share a lot of ultrastructural and distribution
similarities [119]. The developmental programme for ghrelin positive cells appear to be different
between human, mouse and rat (reviewed in [119]), and thus data on developmental pathways for
ghrelin cells elucidated in mice (e.g., [202]) may not apply to humans.
Ghrelin is increased in fasting [203–205]; plasma ghrelin content has a reciprocal relationship
with plasma insulin content [206,207], and has been shown to be an inhibitor of insulin secretion in
human and rodents [208–213]. Ghrelin may also be a regulator of glucagon, PP and somatostatin
release [210,214,215].
8. Conclusions
The cells in the islets have distinct regulatory function and operate within a complex regulatory
network invoking paracrine and neuronal control of energy homeostasis. There are differences in islet
architecture and distribution between human and experimental models, which may have an impact on
islet function and energy homeostasis. Recent reports have indicated islet cells are plastic and that it
may be possible to convert non-β islet cells into β-cells to replenish β-cell mass and function [4,5,7,8].
This knowledge may be important for the development of treatment strategies for diabetes, but will
require careful evaluation of the impact of the loss of a particular non-β islet endocrine cell type on
energy homeostasis.
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